BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21106941)

  • 1. Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 2: clinical studies.
    Lanzani C; Citterio L; Glorioso N; Manunta P; Tripodi G; Salvi E; Carpini SD; Ferrandi M; Messaggio E; Staessen JA; Cusi D; Macciardi F; Argiolas G; Valentini G; Ferrari P; Bianchi G
    Sci Transl Med; 2010 Nov; 2(59):59ra87. PubMed ID: 21106941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 1: experimental studies.
    Ferrandi M; Molinari I; Torielli L; Padoani G; Salardi S; Rastaldi MP; Ferrari P; Bianchi G
    Sci Transl Med; 2010 Nov; 2(59):59ra86. PubMed ID: 21106940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Ouabain- and Adducin-dependent mechanisms of hypertension and cardiovascular remodeling as a novel pharmacological approach.
    Ferrari P; Ferrandi M; Valentini G; Manunta P; Bianchi G
    Med Hypotheses; 2007; 68(6):1307-14. PubMed ID: 17097240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rostafuroxin protects from podocyte injury and proteinuria induced by adducin genetic variants and ouabain.
    Ferrandi M; Molinari I; Rastaldi MP; Ferrari P; Bianchi G; Manunta P
    J Pharmacol Exp Ther; 2014 Nov; 351(2):278-87. PubMed ID: 25187430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihypertensive treatment guided by genetics: PEARL-HT, the randomized proof-of-concept trial comparing rostafuroxin with losartan.
    Citterio L; Bianchi G; Scioli GA; Glorioso N; Bigazzi R; Cusi D; Staessen JA; Cavuto S; Ferrandi M; Lanzani C; Li X; Lau LF; Chiang CE; Wang TD; Wang KL; Ferrari P; Manunta P
    Pharmacogenomics J; 2021 Jun; 21(3):346-358. PubMed ID: 33649520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rostafuroxin: an ouabain-inhibitor counteracting specific forms of hypertension.
    Ferrari P
    Biochim Biophys Acta; 2010 Dec; 1802(12):1254-8. PubMed ID: 20083196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ouabain-dependent signaling in caveolae as a novel therapeutic target for hypertension.
    Ferrandi M; Molinari I; Bianchi G; Ferrari P
    Cell Mol Biol (Noisy-le-grand); 2006 Dec; 52(8):15-8. PubMed ID: 17535730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Main results of the ouabain and adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin.
    Staessen JA; Thijs L; Stolarz-Skrzypek K; Bacchieri A; Barton J; Espositi ED; de Leeuw PW; Dłużniewski M; Glorioso N; Januszewicz A; Manunta P; Milyagin V; Nikitin Y; Souček M; Lanzani C; Citterio L; Timio M; Tykarski A; Ferrari P; Valentini G; Kawecka-Jaszcz K; Bianchi G
    Trials; 2011 Jan; 12():13. PubMed ID: 21235787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PST 2238: A new antihypertensive compound that modulates Na,K-ATPase in genetic hypertension.
    Ferrari P; Ferrandi M; Tripodi G; Torielli L; Padoani G; Minotti E; Melloni P; Bianchi G
    J Pharmacol Exp Ther; 1999 Mar; 288(3):1074-83. PubMed ID: 10027844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OASIS-HT: design of a pharmacogenomic dose-finding study.
    Staessen JA; Kuznetsova T; Acceto R; Bacchieri A; Brand E; Burnier M; Celis H; Citterio L; de Leeuw PW; Filipovský J; Fournier A; Kawecka-Jaszcz K; Manunta P; Nikitin Y; O'Brien ET; Redón J; Thijs L; Ferrari P; Valentini G; Bianchi G
    Pharmacogenomics; 2005 Oct; 6(7):755-75. PubMed ID: 16207152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rostafuroxin: an ouabain antagonist that corrects renal and vascular Na+-K+- ATPase alterations in ouabain and adducin-dependent hypertension.
    Ferrari P; Ferrandi M; Valentini G; Bianchi G
    Am J Physiol Regul Integr Comp Physiol; 2006 Mar; 290(3):R529-35. PubMed ID: 16467500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetics of primary hypertension: the clinical impact of adducin polymorphisms.
    Citterio L; Lanzani C; Manunta P; Bianchi G
    Biochim Biophys Acta; 2010 Dec; 1802(12):1285-98. PubMed ID: 20382219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Association of polymorphism in alpha-adducin gene with antihypertensive effect of Hydrochlorothiazide].
    Wu SL; Li DQ; Li HF; Yu Q; Li Y; Zhao HY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Oct; 33(10):880-4. PubMed ID: 16266470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adducin and hypertension.
    Staessen JA; Bianchi G
    Pharmacogenomics; 2005 Oct; 6(7):665-9. PubMed ID: 16207143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renin-angiotensin system and alpha-adducin gene polymorphisms and their relation to responses to antihypertensive drugs: results from the GENRES study.
    Suonsyrjä T; Hannila-Handelberg T; Fodstad H; Donner K; Kontula K; Hiltunen TP
    Am J Hypertens; 2009 Feb; 22(2):169-75. PubMed ID: 19057513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Losartan with hydrochlorothiazide in the treatment of hypertension.
    Schoenberger JA;
    J Hypertens Suppl; 1995 Jul; 13(1):S43-7. PubMed ID: 18800455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new antihypertensive agent that antagonizes the prohypertensive effect of endogenous ouabain and adducin.
    Manunta P; Ferrandi M; Messaggio E; Ferrari P
    Cardiovasc Hematol Agents Med Chem; 2006 Jan; 4(1):61-6. PubMed ID: 16529550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ouabain antagonists as antihypertensive agents.
    Ferrandi M; Barassi P; Molinari I; Torielli L; Tripodi G; Minotti E; Bianchi G; Ferrari P
    Curr Pharm Des; 2005; 11(25):3301-5. PubMed ID: 16250857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adducin polymorphisms and the treatment of hypertension.
    Manunta P; Citterio L; Lanzani C; Ferrandi M
    Pharmacogenomics; 2007 May; 8(5):465-72. PubMed ID: 17465710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.